TransCon CNP (Navepegritide): A semi-mechanistic model to describe the prolonged half-life of C-type natriuretic peptide through TransConTM technologyPAGE 32 (2024) Abstr 11219 Carlsson Petri KC, Antonescu IE, Gallais F, Brekkan A.ConferenceGeneticPharmacometricsPhase IITrial design and analysisPharmetheus Affiliates Senior Director, MIDD ConsultantFanny GallaisSee bio Senior Director, R&D ScientistAri BrekkanSee bio